Worth reading
61In focus
Scored from 2 of 5 sectionsDirection
Neutral
Direction inferred from the company’s description.Scale
1429900
SharesWording
Definitive
How definitive the wording is.Details of issuance or disposal
Exercise status report for stock acquisition rights with an exercise price adjustment clause
発行・処分する株式数
Number of shares delivered during the month: 1,429,900 shares (1,429,900 new shares and 0 transferred treasury shares)
Existing Shares and Increase
+9.69%Rate of increase
16,999,600 shares18,429,500Shares
9.69% (exercise ratio subject to exercise restrictions)
The dilution rate shows what proportion the newly issued shares represent of the existing shares. The higher the proportion, the more the value and voting rights per share are diluted.
Terms of the stock acquisition rights
Exercise price
22, 23 and 24 June: ¥139; 25 June: ¥145. The floor under the adjustment clause is Not disclosed
Number of Stock Acquisition Rights
Total issued: 36,800; exercised during the month covered: 14,299; unexercised as of the current date: 0
Procedures under the Corporate Code of Conduct
Exercise restrictions were observed in accordance with Rule 434 of the Tokyo Stock Exchange's Securities Listing Regulations and the Japan Securities Dealers Association's Rules Concerning Handling of Third-Party Allotments. The exercise ratio subject to exercise restrictions was 9.69%.
Most recent equity financing
The 29th Series of Stock Acquisition Rights issued by Perseus Proteomics Inc. on 5 January 2026 (total issued: 36,800)
| Item | Details |
|---|---|
| Type of issuance or disposal | Exercise status report for stock acquisition rights with an exercise price adjustment clause |
| Number of shares to be issued or disposed of | Number of shares delivered during the month: 1,429,900 shares (1,429,900 new shares and 0 transferred treasury shares) |
| Dilution Rate | 9.69% (exercise ratio subject to exercise restrictions) |
| Total number of issued shares | 16,999,600 shares (as of the end of the month preceding the month covered) → 18,429,500 shares (the number of shares as of the end of the preceding month plus the number of shares delivered during the month covered) |
| Exercise price | 22, 23 and 24 June: ¥139; 25 June: ¥145. The floor under the adjustment clause is Not disclosed |
| Number of Stock Acquisition Rights | Total issued: 36,800; exercised during the month covered: 14,299; unexercised as of the current date: 0 |
| Procedures under the Corporate Code of Conduct | Exercise restrictions were observed in accordance with Rule 434 of the Tokyo Stock Exchange's Securities Listing Regulations and the Japan Securities Dealers Association's Rules Concerning Handling of Third-Party Allotments. The exercise ratio subject to exercise restrictions was 9.69%. |
| Most recent equity financing | The 29th Series of Stock Acquisition Rights issued by Perseus Proteomics Inc. on 5 January 2026 (total issued: 36,800) |
Items this document does not state (20)
Issue price and disposal priceTotal issue valueAmount of funds to be raisedEstimated issuance expensesSpecific use of fundsPayment dateIntended allotteeIntended allottee's holding policyBasis for determining the amount to be paidExercise periodTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationCategories and Number of Persons CoveredTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioMajor shareholders after the offeringImpact on Business Performance
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To report the large-scale exercise on 25 June 2026 and the completion of exercise of these Stock Acquisition Rights.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.